Pfizer Inc. (NYSE:PFE) Shares Sold by CenterBook Partners LP

CenterBook Partners LP trimmed its position in Pfizer Inc. (NYSE:PFE) by 79.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 61,997 shares of the biopharmaceutical company’s stock after selling 245,797 shares during the period. CenterBook Partners LP’s holdings in Pfizer were worth $1,645,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. PSI Advisors LLC lifted its position in shares of Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. boosted its position in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Lipe & Dalton grew its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC increased its position in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Trading Down 4.1 %

Shares of Pfizer stock opened at $21.57 on Friday. The stock’s 50-day simple moving average is $25.33 and its 200 day simple moving average is $26.45. The stock has a market capitalization of $122.32 billion, a P/E ratio of 15.30, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.